Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.495 AUD | +8.79% | +45.59% | +141.46% |
May. 29 | Euroz Hartleys Adjusts Dimerix’s Price Target to AU$0.86 From AU$0.80, Keeps at Speculative Buy | MT |
May. 27 | Dimerix Signs License Deal for Kidney Disease Medication in the Middle East | MT |
Sales 2022 | 6.47M 4.3M | Sales 2023 | 8.98M 5.98M | Capitalization | 24.06M 16M |
---|---|---|---|---|---|
Net income 2022 | -10M -6.65M | Net income 2023 | -13M -8.65M | EV / Sales 2022 | 4.48 x |
Net cash position 2022 | 9.56M 6.36M | Net cash position 2023 | 2.03M 1.35M | EV / Sales 2023 | 2.45 x |
P/E ratio 2022 |
-3.37
x | P/E ratio 2023 |
-1.46
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 95.78% |
1 day | +8.79% | ||
1 week | +45.59% | ||
1 month | +47.76% | ||
3 months | +120.00% | ||
6 months | +266.67% | ||
Current year | +141.46% |
Managers | Title | Age | Since |
---|---|---|---|
Nina Webster
CEO | Chief Executive Officer | - | 18-08-26 |
Hamish George
DFI | Director of Finance/CFO | - | 19-05-05 |
David Fuller
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nina Webster
CEO | Chief Executive Officer | - | 18-08-26 |
Hugh Alsop
BRD | Director/Board Member | - | 17-04-30 |
Mark Diamond
CHM | Chairman | - | 23-01-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.495 | +8.79% | 11,568,190 |
24-05-30 | 0.455 | +13.75% | 12,106,860 |
24-05-29 | 0.4 | +2.56% | 6,715,744 |
24-05-28 | 0.39 | -8.24% | 12,974,160 |
24-05-27 | 0.425 | +25.00% | 21,770,510 |
Delayed Quote Australian S.E., May 31, 2024 at 02:10 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+141.46% | 181M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- DXB Stock